Professional Role and Current Position
Lihua Yu, Ph.D., serves in a senior leadership capacity at Parabilis Medicines (formerly known as FogPharma). Her confirmed role at Parabilis Medicines includes Chief Data Officer, a position she was appointed to as of November 2021 when FogPharma expanded its executive leadership team. Public acknowledgements from that period confirm her responsibility for leading the company’s data strategy within this clinical-stage biotechnology firm. Parabilis Medicines specializes in innovative drug discovery and development, with the milestone of initiating a first-in-human Phase 1/2 clinical trial for their lead asset, FOG-001, having been announced publicly in June 2023. This indicates active progression into clinical development under her oversight.
Relevant Career History and Expertise
Prior to joining Parabilis Medicines, Lihua Yu held senior data science leadership roles, including:
- Chief Data Officer, LifeMine Therapeutics (as of March 2024), a company advancing a "Top-Down Drug Discovery" strategy focused on novel therapeutic development. Her role at LifeMine underscores expertise in integrating advanced data science capabilities into drug discovery processes.
- President & Chief Data Sciences Officer, H3 Biomedicine, appointed in June 2018. H3 Biomedicine, an Eisai Inc. subsidiary, focuses on cancer genomics-based drug discovery, further confirming Dr. Yu’s specialized experience in leveraging data-intensive approaches for precision medicine and oncology.
Her multi-company tenure demonstrates a consistent emphasis on leadership in data sciences applied to biotech innovation, with a strong focus on translational and clinical-stage initiatives.
Company Context: Parabilis Medicines
Parabilis Medicines, previously known as FogPharma, transitioned to a clinical-stage biotechnology company as of mid-2023, marking advancement from preclinical to clinical testing. The initiation of dosing the first patient in a Phase 1/2 clinical trial for FOG-001 represents a critical development milestone and validates the company’s R&D trajectory. Lihua Yu’s stewardship of data strategies at Parabilis is directly linked to supporting and accelerating these clinical development programs.
The company maintains a presence and following on professional networks indicative of active engagement with healthcare innovation and biotechnology sectors, including participation in panels discussing AI-powered drug discovery and development, reflecting the strategic importance of data sciences within its operating model.
Professional Engagement and Visibility
- Lihua Yu is publicly recognized through LinkedIn posts announcing critical company milestones at Parabilis Medicines, demonstrating a role in external communications related to clinical progress.
- She is featured in MIT alumni events and biotech industry panels, positioning her as a thought leader on integrating AI and data sciences in drug development pipelines.
- Media coverage from industry-specific outlets highlights her executive appointments and contributions, reinforcing her profile as a senior data sciences executive in biotech.
Summary of Actionable Insights
- Dr. Yu is positioned at the nexus of clinical development and data sciences leadership at Parabilis Medicines during a pivotal stage in the company’s growth.
- Her background spans oncology genomics, innovative drug discovery, and translational science, supported by demonstrated leadership roles at LifeMine Therapeutics and H3 Biomedicine.
- The recent transition of Parabilis Medicines to clinical-stage status with an ongoing Phase 1/2 clinical trial reflects organizational momentum that likely depends heavily on effective data strategy and analytics implementation under her direction.
- Engagement in AI-powered drug discovery dialogues suggests openness to cutting-edge technology solutions that could complement Parabilis’s pipeline advancement efforts.
This combination of clinical transition, executive scientific leadership, and demonstrated expertise in data-driven drug discovery underscores Dr. Yu’s strategic importance in advancing Parabilis Medicines’ innovative therapeutics portfolio.
